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Abstract
Antimicrobial Resistance (AMR) is a serious issue because it may reduce treatment effectiveness, increase 
infection transmission and health care costs. This article aims to identify the problems and the implementation 
of the AMR control program in hospital. Method :Data were collected by reviewing study results in journals 
and proceedings, books/literature on AMR at universities and hospitals in Jakarta and Bandung, regulation 
on the distribution and use of antimicrobials at NADFC, control policy on AMR of MoH RI, as well as data of 
nosocomial infections from National Survey on Health Facility (Rifaskes 2011). We also conducted consensus 
decision making which discusses strategic plan and policy for controlling AMR as well as how to optimize or 
strengthen the strategy with participants involving type A hospital AMR Control Committee as keynote speakers 
and Directorate of Referral Health Services, Directorate of Health Service Facility, Directorate of Pharmacy 
Services, Private and Public Hospital Directors in DKI Jakarta, Hospital Accreditation Commission (KARS), 
others researchers and  academicians as stake holders.In Indonesia AMR control program has been started 
in some hospitals, but there are still many obstacles either from the management, facilities or infrastructures 
and practitioners. The policies related to AMR control in Indonesia are stated in Law No. 36 of 2009, Law No. 
44 of 2009 and the Ministry of Health Decree No. 8 of 2015. There is also a guideline of the Ministry of Health 
for Infection Control Program in hospital. These policies should be implemented and used as a tool to increase 
the commitment of the hospital management. Compliance with the guidelines should be strictly implemented, 
besides the rational prescription of antimicrobials, completing facilities and infrastructures for controlling AMR 
and the establishment of surveillance of antibiotic use.
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Abstrak
Resistensi antimikroba (AMR) merupakan masalah serius karena dapat menurunkan efektivitas pengobatan, 
meningkatkan penularan infeksi dan biaya kesehatan. Tujuan kajian adalah mengidentifikasi masalah 
dan penerapan program pengendalian AMR di rumah sakit. Hasil dari berbagai penelitian di rumah sakit 
menunjukkan adanya AMR terhadap beberapa antibiotik. Metode: data berasal dari penelitian dalam jurnal 
dan prosiding, buku tentang AMR di universitas dan rumah sakit di Jakarta dan Bandung, peraturan tentang 
AMR  di badan POM, kebijakan pengendalian AMR di Kemenkes serta data infeksi nosokomial dari Rifaskes 
2011. Kesepakatan keputusan disusun melalui diskusi rencana strategis dan kebijakan pengendalian AMR 
dan penguatan strategi dengan partisipan ARCP dari rumah sakit tipe A sebagai narasumber dan Direktur 
Pelayanan Kesehatan Rujukan, Direktur Fasilitas Pelayanan Kesehatan, Direktur Pelayanan Farmasi, direktur 
rumah sakit pemerintah dan swasta di DKI, Komisi akreditasi rumah sakit, peneliti dan akademisi sebagai 
pemangku kepentingan. Di Indonesia pengendalian AMR sudah dilakukan di beberapa rumah sakit, tetapi 
masih banyak kendala baik dari sisi manajemen, sarana, prasarana dan praktisi. Pengendalian resistensi 
antibiotik di Indonesia diatur berdasarkan peraturan perundang-undangan diantaranya UU No.36 tahun 2009 
tentang kesehatan, UU No.44 tahun 2009 tentang rumah sakit, dan Permenkes RI No. 8 tahun 2015. Ada juga 
pedoman pencegahan dan pengendalian infeksi di rumah sakit yang harus diterapkan guna meningkatkan 
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komitmen pihak manajemen rumah sakit dalam pengendalian AMR. Kepatuhan pada pedoman program 
pengendalian AMR harus ditekankan, selain peresepan antimikroba yang rasional, pemenuhan sarana dan 
prasarana untuk pengendalian dan pembentukan surveilans penggunaan antibiotik.
Kata kunci: resistensi, antimikroba, rumah sakit
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Introduction
 Infectious diseases is one of the biggest 
health problem and the leading cause of death in the 
world.1,2 The main infectious disease medications are 
antimicrobial. Based on the type of microorganisms, 
there are diverse antimicrobials, including antibiotic 
(antibacterial), antiviral, antifungal and the most 
often used is antibiotics.
 The discovery of antibiotics was initiated by 
Paul Ehrlich who found Salvarsan to combat syphilis. 
Then followed by the Alexander Fleming who 
accidentally discovered penicillin to treat infections 
of Staphylococcus aureus. Other antibiotics, sulfa 
was discovered by Gerhard Domagk that pave the 
way for the anti-TB drug discovery, isoniazid. In 
1943, streptomycin was discovered by Selkman 
Wakzman and Albert Schatz. Wakzman also the first 
person to introduce the terminology of antibiotics. 
Since that time antibiotics have been widely used by 
clinicians to handle a variety of infectious diseases.2,3 
 During 1940 to 1970 period, many new 
antibiotics had been found such as Chloramphenicol, 
Framycetin, Bacitracin, Spiramycin, Nystatin, 
Cephalosporin, Rifamycin, Nebramycin, 
Streptomycin and others, but starting from 1980 to 
2000 new antibiotics had been rarely found. Even 
the last 14 years there is no invention of brand new 
antibiotics, but simply replication/third generation.4 
Method
 Data were collected by reviewing study 
results in journals and proceedings, books/literature 
on AMR at universities and hospitals in Jakarta and 
Bandung, regulation on the distribution and use of 
antimicrobials at NADFC, control policy on AMR 
of MoH RI, as well as data of nosocomial infections 
from National Health Facility Research (Rifaskes 
2011). We also conducted consensus decision 
making which discusses strategic plan and policy 
for controlling AMR and that has already been done 
including the results, as well as how to optimize or 
strengthen the strategy with participants involving 
type A hospital AMR Control Committee as keynote 
speakers and Directorate of Referral Health Services, 
Directorate of Health Service Facility, Directorate of 
Pharmacy Services, Private and Regional Hospital 
Directors in DKI Jakarta, Hospital Accreditation 
Commission (KARS), Jakarta Health Office,  others 
researchers and  academicians as stake holders.
The antimicrobial resistance
 Resistance can be defined as no inhibition of 
the growth of bacteria by administering antibiotics 
systemically with normal doses.While the multiple 
drug resistance is defined as the resistance to two 
or more drugs or drug classifications and cross 
resistance is resistance to a drug that is followed by 
other medications that have never been exposed.3
Factors that favor the occurrence of resistance, 
among other things:
1. Inappropriate use (irrational)
 Example: use of antibiotics for a time 
too short, too low a dose, wrong early diagnosis, 
inadequate potential.
2. Wrong knowledge of the patient
 The wrong patient knowledge that considers 
antibiotics can cure a variety of infectious diseases, 
including infections caused by viruses, such as 
flu, cough-cold and fever are encountered in the 
community. Patients with good financial capability 
will ask for the most recent and costly antibiotic 
therapy even though not required. Moreover, 
patients can buy antibiotics without prescription 
(self-medication). While patients with low financial 
capability can hardly afford to complete the therapy 
regimen.
3. Prescription
 Antibiotics are often already prescribed, 
although the diagnosis is still uncertain. Clinicians 
often met difficulties in determining the proper 
antibiotics because of the lack of training in terms of 
infectious diseases and antibiotic treatment.
4. The use of monotherapy
 The use of monotherapy poses resistance 
more easily compared with the use of combination 
therapy.
5. Use of antibiotics in hospitals
 The existence of endemic or epidemic 
infection triggers a more massive use of antibiotics 
in an inpatient ward especially in the intensive care 
unit. The combination of more intensive and longer 
antibiotic used for patients who are very sensitive to 
infections, facilitates the occurrence of nosocomial 
infections.
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6. Antibiotics use for animals and cattle
 In farms, a large amount of antibiotic is used 
in routine supplement as prophylaxis or to stimulate 
the growth of farm animals. When used in a sub 
therapeutic dose, it will increase the occurrence of 
resistance.
7. Commercial promotion and the massive sales by 
pharmaceutical companies makes the amount of 
available antibiotic in abundance.
8. Research
 The discovery of a new antibiotic study is 
languishing that no new antibiotics found.
9. The supervision
 Weak government control over the 
distribution and use of antibiotics, such that 
anyone can easily get antibiotics without a doctor’s 
prescription3,5
ISSUES
The problem of antibiotic resistance is an important 
issue because:
• Infections caused by resistant bacteria are 
often cannot be successfully treated using the 
standard treatment of antibiotics. Consequently, 
it will cause longer periods of hospitalization in 
a hospital (length of stay),raise morbidity and 
mortality rates and health costs.
• Antibiotic resistance will decrease the 
effectiveness of treatment and enhance the 
occurrence of infection to others. When 
treatment failed, the patient become infectious 
for several extended periods (carrier). This 
provides a greater opportunity for resistant 
strains to spread to others. The development of 
transportation technology will accelerate the 
spread of antimicrobial resistance whilst no 
new antibiotics found and the rise of antibiotic 
resistance would lead to a situation like at the 
time of the pre-antibiotic era6,7 Therefore, it is 
very appropriate Slogan of the WHO on World 
Health Day in 2011, “Combat Drug Resistance, 
No Action today, No Cure tomorrow” The 
purpose of this study is to identify the types of 
resistant microbes, its control and problems in 
the implementation of the Antibiotic Resistance 
Control Program (ARCP) in the hospital.
FINDING AND DISCUSSION
a. The Situation of Antimicrobial Resistance in 
Various Countries
 The success of penicillin therapy did not 
last long with the emergence of resistant strains 
containing gene blaZ that decode the beta-lactamase 
enzymes i.e., an enzyme that is able to degrade 
penicillin. At the end of the 1950s, this problem 
can be overcome by administering antibiotics 
resistant to beta-lactamase i.e. methicillin. About 
a year after the use of methicillin, strains of S. 
aureus resistant methicillin called MRSA emerged. 
The main resistance determinant on MRSA is gen 
mecA in the Staphylococcal Cassette Chromosome 
mec (SCCmec). MRSA outbreaks first occurred in 
Europe in the era of the 1960s, then spread rapidly 
to numerous hospitals worldwide, so that MRSA 
is often also called Healthcare-Associated MRSA 
(HA-MRSA). These bacteria are multiresistant. The 
average prevalence of MRSA in hospitals in the 
world ranges between 20-40 percent. In 1998 in the 
United States the existence of a new strain of MRSA 
was reported, that is Community-Associated MRSA 
(CA-MRSA) which is non-multiresistant but more 
virulent than HA-MRSA. The spread of MRSA 
was further expanded both in the hospital and in the 
community. In the United States, about 25 percent of 
isolates of S. aureus causing infection in hospital is 
MRSA. Prevalence lower than 5% can be found in 
the Netherlands and some Scandinavian countries, 
where the use of antibiotics is very constricted. This 
is one of the keys to the success of MRSA infection 
control in those countries2 
 Testing the sensitivity of strains from 1824 
patients with sputum TB positive by Yan Shao et 
al in Jiangsu Province, China, against rifampicin, 
isoniazid, ethambutol and streptomycin suggests 
that 1077 (59.05%) MTB strains are sensitive to 
antibiotics and 747 (40.95%) strains are resistant 
to at least medication. The proportion of resistance 
to one drug is 28.73% to isoniazid, 19.41% to 
rifampicin, 29.33% to streptomycin, and 13.98% to 
ethambutol. The prevalence of MDR-TB is 16.61%, 
and significantly different between new cases 
(7.63%) and cases with previous treatment (33.07%). 
Patients with previous treatment had MDR TB risk 
5 times (adjusted OR: 6.14, 95% CI: 4.61-8.17), 
compared to no previous treatment. High prevalence 
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of drug resistance is a big challenge in controlling 
TB. Resistant TB prevention and control should 
be emphasized with the revised program DOTS 
(directly observed therapy, short term) through early 
case detection, good routine sensitivity testing for 
patients with a high risk of resistance, programmatic 
management with first and second-line drugs as well 
as systematic observation of treatment with priority 
on high MDR-TB setting8 Case-control study of 
the causes of anti-tuberculosis drug resistance in 
Bandung shows that previous inadequate treatment 
history factor is the leading cause.9 
b. The Situation of Antimicrobial Resistance in 
Indonesia
 Currently Indonesia has not had a proper 
antibiotic resistance map. Existing resistance data 
from various studies are still sporadic in nature, 
location and time of study are different, as well 
as the number of samples, methods, and types of 
antimicrobial used is varying.
Noviana reported that MRSA prevalence based on 
sensitivity test to various antimicrobials in Jakarta’s 
Atmajaya Hospital in 2003 reached 47 percent, 
likewise Yuwono also reported that MRSA incidence 
in RSU Dr. Mohammad. Hoesin, Palembang reached 
46 percent. Currently only vancomycin and a small 
kind of antibiotics that can be used to treat MRSA 
infections.2
 The results of the study by Krisni 
Subandiyah for 1 January 1999 until 31 December 
2003 on 563 patients suspect a urinary tract infection 
(UTI) in RSU Dr. Saiful Anwar, Malang shows 
thatciprofloxacine,cefotaxim, and amikasin are 
still sensitive to P. aeruginosa, E. coli, A. anitratus, 
A. hydrophilia, E. aerogenes, E. anglomerans, E. 
gingivae, P. mirabilis, S. coagulase negative, whereas 
ampicillinis only sensitive to S. coagulase negative 
and nitrofurantoin is only sensitive to E. Coli.10 
Research by Keni Istasaputri M. et al between 19 
September and October 31, 2011 on 22 patients 
with atopic dermatitis (DA) in Clinic of skin and 
sex of RSU Hasan Sadikin showed that S. aureus 
nurtured in as many as 17 of the 22 patients and 
there was a growth of MRSA strains in 3 patients. 
Gentamycin, tetracycline and neomycin have been 
already resistant toS. aureus on 6 of 17 patients with 
S. aureus, just like3 patients with MRSA strains.11 
The study of Usman Hadi stated that:
1) Infection with ESBL-producing bacteria had 
increased in hospitals and had reached a critical 
point that raises serious concerns.
2) Prevalence of ESBL varied between hospitals 
and the specimen due to differences in the use of 
antibiotics and policies.
3) Between Escherichia coli and Klebsiella 
pneumoniae, the average prevalence of resistance 
ranged from 26 to 56%.
4)   The pattern of antibiotic sensitivity indicated 
there was only a small choice of antibiotics for 
treatment of ESBL-producing bacterial infection 
such as amikacin, phosphomycin, meropenem, 
tigecycline.
5)  The main challenge of implementation of 
Antimicrobial Resistance Control Programs (ARCP) 
was the rise of wisely used antibiotics and adherence 
to SOPs.12 
 Laboratory examination in National Center 
General Hospital Cipto Mangunkusumo during the 
years 2010 - 2012 indicates that there have been 
many antibiotics that have the sensitivity lower 
than 50%. They are among others, piperacillin/
tazobactam, sulbactam, cefoperazone/cefpirome, 
tetracycline, cephalothin, and others from the 
class of tetracycline, penicillin, cephalosporin, 
aminoglycoside, macrolide, quinolone, and 
carbapenem.13 
c. Antimicrobial Resistance Control Program in 
Various Hospitals
 The implementation of the Antimicrobial 
Resistance Control Program (ARCP) in hospitals, 
aims to improve the quality of health services, 
particularly in handling of infection case in the 
hospital, reducing the antimicrobial resistance, 
preventing toxicity due to antimicrobial use, lowering 
costs due to unwise use of the antimicrobials and 
lowering the risk of nosocomial infections, as well 
as enabling to minimize the risk of occurrence of 
medical errors in the hospital. It is estimated that 
50 percent of prescriptions given to patients is not 
necessary because it is usually only for the treatment 
of colds, coughs and viral infections.14,15
 Controlling antimicrobial resistance requires 
the collaboration of various health professions, 
among others, a doctor, a nurse, a pharmacist, and a 
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microbiologist. In Canada, antimicrobial resistance 
control efforts began in 1997 that included 3 things, 
namely antimicrobial management, surveillance 
to monitor the trends of resistance as well as the 
prevention and control of infection16  Implementation 
of healthcare related infection surveillance 
(Healthcare Associated Infections/HI) performed by 
most European countries and the United States has 
been shown to reduce the incidence of infections in 
Europe and the United States, despite differences 
or variations in the methods of surveillance.17 2011 
Health Facilities Research states that approximately 
51.7% government general hospital has been 
equipped with Committee to combat nosocomial 
infections, but not all of them active, about 84% are 
active.18 
 Antimicrobial resistancecaused 
inefficiencies up to US $ 4-5 billion in the US and 
up to € 9 billion per year in Europe. Adverse drug 
reaction and medication error is estimated to have 
cost of 3.4 million dollars per year. One of the 
impacts of the control program for antibiotic use 
in hospitals was a cost savings of $ 17 million in 8 
years.19 
 On the World Health Day in 2011, the 
WHO set the recommendations relating the use 
of antibiotics in the hospital among other capacity 
building in surveillance and laboratory capabilities, 
ensuring continuous essential drug access with good 
quality, promoting and controlling rational drug 
use and providing adequate patient care, as well as 
improving prevention and infection control.20 
 In the same year, Member State in the WHO 
SEARO stated “JAIPUR DECLARATION”. As 
for the content of the agreement related to hospital, 
among others, the development of National Antibiotic 
Policy, setting the use of antibiotics in both public 
and private sectors, changes in the behavior of the 
prescriber and the community in the rational use of 
antibiotics and including national essential drug list/
NEDL.21 
 The surveillance system is one of the 
important stages of resistance control efforts, 
therefore the WHO has issued a standard surveillance. 
Preferably the antimicrobial resistance surveillance 
comprises the collection of data and clinical purity.
Antimicrobial Resistance Control Programs in 
Hospitals in Different Countries.
 The commitment of the United Kingdom 
(UK) to address antimicrobial resistance and to 
respond to the AMR 2011 EU Strategic Action Plan 
and 2012 EU Council Conclusions,  emphasizes 
several areas for the next actions at hospitals 
amongst others an increase in infection prevention 
and control practices, optimization of prescribing 
practices, an upgrade of professional education, 
training and public engagement, better access and 
use of surveillance data, improved identification 
and prioritization of AMR studies and stronger 
international cooperation.22 
 The Government of India has also set policy 
on antimicrobial resistance (National policy for the 
containment of AMR India) which aims to:
a. Understand the incidence and spread of 
antimicrobial resistance and the affecting factors.
b.  Establish a well-coordinated national antimicrobial 
program.
c. Rationalize the use of antimicrobials.
d. Reduce antibiotic selection pressure with adequate 
control measures.
e. Increase the discovery of newer and more effective 
antimicrobial.
f. Diagnose precisely infections and infectious 
diseases
 The implementation of the policy is, among 
otherthings the establishment of surveillance 
program, the increase of rational use of antimicrobials, 
infection control and prevention programs, studies 
on antimicrobials, and monitoring and evaluation.23 
C.1. Antimicrobial Resistance Control Program in 
Hospitals in Indonesia
Legal basic
-  Law of the Republic of Indonesia No. 36 of 2009 
about health.
Article 5 paragraph 2 states that everyone bears 
the right to receive health services that are safe, 
high quality, and affordable. The Government is 
responsible for the availability of all forms of health 
care efforts that are high quality, secure, efficient, and 
affordable (article 19)24 As one form of administering 
health services that are safe and of good quality, the 
Government was supposed to make regulations that 
require hospitals to do ARCP.
-  Law of the Republic of Indonesia No. 44 of 2009 
about hospital. 
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One purpose of making a hospital to conduct 
services is to ensure the safety of patient, community, 
environment and human resources in hospital (article 
3). A hospital has an obligation to provide health 
services that are safe, high quality, indiscriminate, 
and effective in accordance with standard services, 
as well as mandatory standards of patient safety.25 
- Decree of MoH Republic of Indonesia no. 382/
Menkes/SK/III/2007 on guidelines for theprevention 
and control of Infection in hospital and other health 
facilities.
 These guidelines are expected to be a 
reference to implement prevention and control of 
hospital infection, so as to protect health workers 
and the public from the spread of infectious diseases 
(Emerging Infectious Diseases).26 
- Decree of MoH Republic of Indonesia no. 2406/
MENKES/PER/XII/2011 on General Guidelineson 
the use of Antibiotics
 Aside from being a national reference in 
setting up policies and guidelines of antibiotic use 
for hospital and other health care facilities, these 
guidelines set the need for assessment of antibiotic 
use in hospital and antimicrobial stewardship 
program in health care facilities.5 
-  Decree of MoH Republic of Indonesia no. 8 of 2015 
about Antimicrobial Resistance ControlProgram 
(ARCP).
 The decree is used as a reference for hospital 
in an attempt to control the resistance so that the 
ARCP in hospital takes place in standardized, 
scalable and integrated manner.27 Some large (type 
A) hospital as National Center General Hospital 
Cipto Mangunkusumo, Dr. Sutomo and Hasan 
Sadikin hospital has formed an ARCP Team. The 
main task of the ARCP team is to help the leadership 
of the hospital to:
a. Set up a policy for controlling antimicrobial 
resistance at the hospital.
b.  Establish implementation of ARCP in hospital.
c. Disseminate and enhance understanding of 
antimicrobial resistance control in hospital, which is 
closely related to proper use of antimicrobial wisely 
and implementation of the principles of infection 
control.
d. Develop integrated research related to 
antimicrobial resistance control in hospital.
e.       Monitoring and evaluation of the implementation 
of the ARCP intensively.
 In running the task, ARCP team always 
coordinate with the Medical Committee, the Hospital 
Patient Safety Committee (KPRS), the Infection 
Control Committee (DALIN), the Pharmacy and 
Therapeutics Committee, the Clinical Microbiology 
Installation and the Hospital Pharmacy Installation28 
c.1.1.  ARCP in Cipto Mangunkusumo National 
Center General Hospital
 An ARCP team of National Center General 
Hospital Cipto Mangunkusumo has already been 
formed since July 2009 but ARCP implementation 
in the hospital is not yet satisfactory. As a result, 
improved quality of antimicrobial use has not 
seemed significant. The pattern of resistance germs 
also hasn’t decreased noticeably, but the rationality 
of antimicrobial use began to appear. Starting from 
February 2012 each patient who are treated with 
antibiotics has been recorded in the monitoring card 
for antibiotic use that are attached to the medical 
record. The role of the ARCP working group at the 
department level is still lacking. 
 Dissemination and socialization is not 
optimal yet. Responses of clinical doctors both 
for doctors in charge of services and for specialist 
residents are still lacking, perhaps due to such a 
heavy workload that ARCP is often overlooked. 
This suggests that the importance of controlling 
antimicrobial resistance has not been well understood. 
Therefore, the promotion and dissemination of ARCP 
among clinicians are crucial, especially for gaining 
similar conception in order to develop an attitude 
and behaviour that supports the success of ARCP. 
The next target of the promotion and dissemination 
are medical students at the clinical level, paramedics 
as well as others associated with infections in 
the hospital. Accreditation by Joint Commission 
International (JCI) is actually a good momentum 
since antimicrobial resistance control is also used as 
a benchmark for performance indicators.28,29 
 Barriers to ARCP is a bed occupancy rate 
(BOR) that often exceeds capacity, difficulty in 
coordination to perform ARCP, the role of the 
ARCP working group at the department level is still 
inadequate, dissemination and socialization are too 
slow, the unresponsiveness of clinician/physician as 
well as a very heavy workload.29 
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c.1.2. ARCP in Dr. Sutomo Provincial Hospital
 Since its formation in 2009, ARCPteam has 
gained results, among others:
1. Increased awareness of clinicians to examine 
culture, namely 29.75% to 64.56%.
2. Data turnaround time that describes the 
performance of microbiological examination is better 
so the patient can immediately get microbiological 
results to improve or ensure the diagnosis made by 
clinicians.
3.    Improvement of the appropriateness of antibiotics 
uses from 52.94% to 65%.
4.  Save antibiotic expenditures amounting to Rp. 
203,000 per patient during hospitalization.
5.  Increase the awareness of the clinicians to 
examine culture.28
c.1.3. ARCP in Dr. Hasan Sadikin Provincial 
Hospital
 Since it was formed in 2009, ARCP has 
shown progresses, among othersantibiotic policy 
& antibiotic guideline (guideline for controlling 
antibiotic resistance), pattern of germs data, antibiotic 
used record, quantitative and qualitative audit results 
of antibiotic and surveillance of hospital infections 
(SIRS).
 However, there are still obstacles i.e. 
human resources, formularies enactment, antibiotic 
restriction.30 
 In addition, in the year 2012 an ARCPpilot 
projectat 20 hospitals was conducted by ARCP 
working group of the Ministry of Health Republic of 
Indonesia. The results of the pilot project include:
• Determination of policy on ARCP 
implementation is conducted by 59.1% hospital, 
whereas the determination of long, medium and 
short term ARCP by 22.7% hospital.
• ARCP coordination meetings are done by 31.8 
% hospital, and direction of hospital executive at 
an ARCP coordination meeting by 27.3%.
• Establishment of the hospital ARCP team 
organization that at least involves elements of 
clinicians, microbiology laboratory, pharmacy, 
Pharmacy and Therapeutics Committee and 
Infection Prevention and Control Committee is 
done by 68.2% hospital, while determination 
of organizational structure that describes 
operational and coordination function by 40.9% 
and determination of descriptions of tasks, 
functions, authority, responsibility of the ARCP, 
in written form, by 45.5% hospital.
• The establishment of working program and 
schedule of activities by 40.9% hospital, ARCP 
socialization, coordination meetings, study 
cases of infectious diseases forum conducted by 
22.7% hospital.
• Policy on antibiotic use control set by the 
leadership of 18.2% hospital and antibiotic use 
guidelines endorsed by the leadership of the 
hospital amounted to 6.8%.
• The existence of competent personnel in 
microbiology (clinical microbiologist or 
clinical pathologist or well-trained doctor or 
well-trained analysts) is 50%, microbiological 
examination, including painting and/or culture 
examination and antibiotic sensitivity testing 
is performed by 43.2% and existing data is 36, 
4%, while communication between clinicians 
and laboratory microbiology in the treatment 
of infectious diseases is only done by 6.8% 
hospital.
• Warrant the availability of appropriate antibiotics 
in guideline and formulary conducted by 38.6% 
hospital, whereas clinical pharmacy activities 
and reports findings of Drug Related Problems 
concerning antibiotic use and the logging of 
antibiotics use recorded completely in written 
form is only done by 9.1% hospital. As for 
communication and consultation between the 
pharmacist, clinicians, microbiology laboratory 
staff and nurses on treatment of infectious cases 
is only done by 6.8% hospital.
• Implementation of the Prevention and Control 
of Infection (PPI) which consist of the existence 
of committees/subcommittee assigned by the 
hospital leadership (81,8%), the availability of 
means of communication and administration, 
which support the activities of PPI (54.6%), 
the presence of PPI manual and guide on 
outbreak management confirmed by the hospital 
leadership (50%), the availability of facilities 
for infection prevention and control as well 
as hand-washing guidelines and APD (27%)), 
the existence of hospital infection surveillance 
activities and follow-up at regular intervals 
(24.2%).
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• Periodic evaluation of antibiotic use is still very 
low (< 10%), whereas education and training 
is even lower (< 5%). Furthermore, periodic 
meeting of infectious diseases is not done in all 
hospitals that became the pilot project.31 
 Based on the above findings shows that many 
hospitals are not yet ready to conduct PPI, especially 
in terms of infrastructure, clean water sterilization 
and processing waste, mostly hospitals of classes C 
and D. Sewage treatment is important in the control 
or prevention of spread of antimicrobial resistance. 
This program gives many benefits especially in 
preventing the occurrence of total resistance or back 
to the era before antibiotics.32
Conclusion
 Microbial resistance from a variety of 
research results and data in the hospital is already 
alarming. On the other hand, the government 
hospitals are not ready to do an ARCP in terms of 
human resources, facilities and infrastructure.The 
commitment of the hospital leadership is lacking to 
fully support the ARCP.
Recomendation
 These policies should be implemented 
and used as a tool to increase the commitment of 
the hospital management. Compliance with the 
guidelines should be strictly implemented, besides the 
rational prescription of antimicrobials, completing 
facilities and infrastructures for controlling AMR 
and the establishment of surveillance of antibiotic 
use.
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